Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Jemperli

- PMLiVE

CSL’s Privigen approved as measles treatment by European Commission

Cases of measles have been rising in Europe since 2023

- PMLiVE

GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B

Over 240 million people worldwide live with chronic hepatitis B

- PMLiVE

GSK signs agreement with Protas to streamline clinical trials

The new three-year agreement builds on an existing two-year relationship

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE

Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

The drug is already approved in the EU across three other multiple myeloma indications

- PMLiVE

J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links